News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
707,751 Results
Type
Article (41993)
Company Profile (334)
Press Release (665424)
Section
Business (210227)
Career Advice (2081)
Deals (36593)
Drug Delivery (100)
Drug Development (82867)
Employer Resources (171)
FDA (16491)
Job Trends (15364)
News (355583)
Policy (33844)
Tag
Academia (2577)
Alliances (51195)
Alzheimer's disease (1275)
Approvals (16441)
Artificial intelligence (157)
Bankruptcy (363)
Best Places to Work (11718)
Biotechnology (216)
Breast cancer (191)
Cancer (1391)
Cardiovascular disease (116)
Career advice (1742)
Cell therapy (285)
Clinical research (66243)
Collaboration (495)
Compensation (263)
COVID-19 (2613)
C-suite (110)
Data (1400)
Diabetes (174)
Diagnostics (6257)
Earnings (86581)
Employer resources (149)
Events (112912)
Executive appointments (402)
FDA (17172)
Funding (433)
Gene therapy (206)
GLP-1 (632)
Government (4454)
Healthcare (18886)
Infectious disease (2705)
Inflammatory bowel disease (115)
Interviews (320)
IPO (16620)
Job creations (4053)
Job search strategy (1489)
Layoffs (439)
Legal (8326)
Lung cancer (199)
Lymphoma (100)
Manufacturing (215)
Medical device (13305)
Medtech (13310)
Mergers & acquisitions (20123)
Metabolic disorders (471)
Neuroscience (1607)
NextGen Class of 2024 (6636)
Non-profit (4526)
Northern California (1701)
Obesity (269)
Opinion (208)
Patents (120)
People (58441)
Phase I (20515)
Phase II (29153)
Phase III (21861)
Pipeline (518)
Postmarket research (2651)
Preclinical (8732)
Radiopharmaceuticals (242)
Rare diseases (271)
Real estate (6247)
Regulatory (22521)
Research institute (2361)
Resumes & cover letters (358)
Southern California (1468)
Startups (3716)
United States (15336)
Vaccines (583)
Weight loss (197)
Date
Last 7 days (591)
Last 30 days (2345)
Last 365 days (35731)
2024 (35568)
2023 (40643)
2022 (51808)
2021 (56341)
2020 (54814)
2019 (47434)
2018 (35798)
2017 (33165)
2016 (32687)
2015 (38627)
2014 (32530)
2013 (27645)
2012 (29744)
2011 (30499)
2010 (28506)
Location
Africa (777)
Arizona (202)
Asia (40151)
Australia (6433)
California (3836)
Canada (1455)
China (311)
Colorado (174)
Connecticut (180)
Europe (85533)
Florida (535)
Georgia (135)
Illinois (394)
Indiana (232)
Maryland (634)
Massachusetts (3009)
Michigan (174)
Minnesota (291)
New Jersey (1117)
New York (1086)
North Carolina (762)
Northern California (1701)
Ohio (146)
Pennsylvania (929)
South America (1159)
Southern California (1468)
Texas (557)
Utah (109)
Washington State (406)
707,751 Results for "catalyst pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst’s management team, will participate at the upcoming Jefferies Global Healthcare Conference 2024 on Wednesday, June 5, 2024, in New York.
May 28, 2024
·
3 min read
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
Catalyst Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has approved its supplemental New Drug Application (“sNDA”) increasing the indicated maximum daily dose of FIRDAPSE.
May 30, 2024
·
4 min read
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
Catalyst Pharmaceuticals, Inc. today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst’s management team, will participate at the upcoming BofA Securities Health Care Conference.
May 1, 2024
·
3 min read
Press Releases
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 16, 2024
·
2 min read
Business
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today reported financial results for the first quarter of 2024 and provided a business update.
May 8, 2024
·
12 min read
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX) today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst’s management team, will participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium taking place virtually on April 2-3, 2024.
March 27, 2024
·
3 min read
Press Releases
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences - November 19, 2024
November 20, 2024
·
2 min read
Press Releases
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
November 14, 2024
·
3 min read
Deals
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share.
January 5, 2024
·
4 min read
BioMidwest
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Catalyst Pharmaceuticals, Inc. announced that it has commenced an underwritten public offering of $150,000,000 of its common stock.
January 4, 2024
·
4 min read
1 of 70,776
Next
